The historical rank and industry rank for Lyra Therapeutics's Days Payable or its related term are showing as below:
LYRA's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
Lyra Therapeutics's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
Lyra Therapeutics Days Payable Related Terms
Lyra Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Lyra Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYRA vs EVFM, CLSDQ, ATXI: Days Payable Comparison
For the Biotechnology subindustry, Lyra Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lyra Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyra Therapeutics (LYRA) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lyra Therapeutics and its competitors. According to the industry distribution chart, Lyra Therapeutics ranks #999999 out of 699 companies in the Biotechnology industry.
Is Lyra Therapeutics' Days Payable too high?
Lyra Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Lyra Therapeutics ranks #999999 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyra Therapeutics has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Days Payable compare to EVFM and CLSDQ?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #999999 out of 699 companies for Days Payable. This places Lyra Therapeutics in the lower half of its industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lyra Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyra Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.53, compared to a current price of $0.51 — trading 79.8% below its estimated fair value. The current Days Payable is 0.00. Lyra Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyra Therapeutics (LYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued.
The current stock price of $0.51 is trading 79.8% below its estimated GF Value™ of $2.53.
GuruFocus considers Lyra Therapeutics to be Possible Value Trap.
Key valuation signals for LYRA:
Days Payable: 0.00
GF Value™: $2.53 vs. price of $0.51 (79.8% below fair value)
No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
25GF Score
Get the complete analysis for LYRA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
